News
Fuzeon Is Unable to Block Transmission During Birth
Fuzeon Is Unable to Block Transmission During Birth

By continuing to use our site, you agree to our Private Policy and Terms of Use.
Fuzeon Is Unable to Block Transmission During Birth
Fuzeon Is Unable to Block Transmission During Birth
Fuzeon, the HIV fusion inhibitor marketed by Roche and Trimeris, does not prevent mother-to-child transmissions of HIV, according to a case report of an HIV-positive woman in San Francisco who infected her child during birth. The woman had an undetectable blood-based viral load, but genetic tests showed the only active drug in the woman's antiretroviral regimen was Fuzeon. The medication might not have penetrated the genital tract enough to suppress vaginal HIV levels, researchers at the University of California, San Francisco, report in the June 10 edition of the journal AIDS.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.